Move aside April 20, also known as "420 Day." The cannabis industry now has a more important date to celebrate – Dec. 18.
Last Thursday, Dec. 18, 2025, President Donald Trump issued an executive order calling for the reclassification of marijuana from a Schedule I classification to a Schedule III classification. Michael Bronstein, President of the American Trade Association for Cannabis and Hemp, called the decision "the most significant federal shift in cannabis policy in over 50 years."
As you might expect, President Trump's move has significant implications for cannabis companies. But are three of the biggest marijuana stocks, Green Thumb Industries (GTBIF +2.24%), Tilray Brands (TLRY +1.25%), and Trulieve Cannabis (TCNNF +3.64%), now no-brainer buys?
Image source: Getty Images.
What reclassification of marijuana means
Former President Richard Nixon signed the Controlled Substances Act into law in 1970. It classified marijuana as a Schedule I drug, which meant it was found to have "no currently accepted medical use and a high potential for abuse."
President Trump's recent executive order directs Attorney General Pam Bondi to "take all necessary steps" to reschedule marijuana to Schedule III. This schedule is defined as "drugs with a moderate to low potential for physician and psychological dependence."
This action recognized that marijuana has legitimate medical uses, making the Schedule I classification inappropriate. It also reflected the reality that 40 U.S. states, three territories, and the District of Columbia have legalized the use of medical cannabis.
Importantly, though, marijuana remains illegal at the federal level in the U.S. Trump emphasized that his executive order "doesn't legalize marijuana in any way, shape, or form, and in no way sanctions its use as a recreational drug."
How the move affects Green Thumb, Tilray, and Trulieve
Green Thumb, Tilray, and Trulieve will be affected in several positive ways by the reclassification of marijuana. The CEOs of all three companies praised the Trump administration's decision.
Perhaps the most critical impact for Green Thumb, Tilray, and Trulieve is that they will be exempt from IRS Code Section 280E. This section of the IRS code prevents companies in the cannabis industry from deducting some business expenses, including payroll and rent.
OTC: GTBIF
Key Data Points
Exemption from Section 280E could boost the profits of cannabis companies. What companies do with this extra money could have far-reaching consequences as well. For example, they could increase their marketing efforts, which could drive both revenue and profits higher.
The reclassification of marijuana to Schedule III may also lead to expanded access to financial services. Some banks have been reluctant to work with cannabis companies in the past due to the legal murkiness with marijuana being legal in many states but illegal at the federal level.
NASDAQ: TLRY
Key Data Points
In addition, Trump's move could attract more investors to marijuana stocks. Reclassification is already spurring greater investment in one way. Tilray announced plans to expand its U.S. medical cannabis operations following the White House's announcement related to rescheduling marijuana.
Are these marijuana stocks no-brainer buys?
Rescheduling marijuana is, without question, a significant milestone for the U.S. cannabis industry. Does it make Green Thumb, Tilray, and Trulieve stocks no-brainer buys? No.
OTC: TCNNF
Key Data Points
For example, Tilray is currently unprofitable. The Canadian company posted a net loss of $793.5 million in the third quarter of 2025. Trulieve is also unprofitable, with the Florida-based company recently reporting a Q3 net loss of $27 million.
Green Thumb's valuation could be an issue for some investors. The Illinois-based cannabis operator's shares trade at a forward price-to-earnings ratio of 34.6.
Each marijuana stock must be viewed on its own merits, with all factors taken into consideration. Marijuana reclassification is an important factor, but it's not the only one.
